X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CIPLA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CIPLA AUROBINDO PHARMA/
CIPLA
 
P/E (TTM) x 14.9 29.3 50.8% View Chart
P/BV x 3.0 3.1 96.8% View Chart
Dividend Yield % 0.4 0.5 76.3%  

Financials

 AUROBINDO PHARMA   CIPLA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
CIPLA
Mar-18
AUROBINDO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs809663 122.0%   
Low Rs504479 105.2%   
Sales per share (Unadj.) Rs281.1189.0 148.7%  
Earnings per share (Unadj.) Rs41.417.6 235.0%  
Cash flow per share (Unadj.) Rs50.934.0 149.5%  
Dividends per share (Unadj.) Rs2.503.00 83.3%  
Dividend yield (eoy) %0.40.5 72.5%  
Book value per share (Unadj.) Rs199.4176.7 112.8%  
Shares outstanding (eoy) m585.88805.12 72.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.33.0 77.3%   
Avg P/E ratio x15.932.5 48.9%  
P/CF ratio (eoy) x12.916.8 76.9%  
Price / Book Value ratio x3.33.2 101.9%  
Dividend payout %6.017.1 35.5%   
Avg Mkt Cap Rs m384,630459,724 83.7%   
No. of employees `00017.323.6 73.4%   
Total wages/salary Rs m21,30826,901 79.2%   
Avg. sales/employee Rs Th9,500.76,446.1 147.4%   
Avg. wages/employee Rs Th1,229.41,139.4 107.9%   
Avg. net profit/employee Rs Th1,397.9600.0 233.0%   
INCOME DATA
Net Sales Rs m164,666152,193 108.2%  
Other income Rs m1,0203,577 28.5%   
Total revenues Rs m165,686155,769 106.4%   
Gross profit Rs m37,71828,264 133.4%  
Depreciation Rs m5,58013,228 42.2%   
Interest Rs m7771,142 68.0%   
Profit before tax Rs m32,38017,470 185.4%   
Minority Interest Rs m310-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m8,1832,501 327.2%   
Profit after tax Rs m24,22914,166 171.0%  
Gross profit margin %22.918.6 123.3%  
Effective tax rate %25.314.3 176.5%   
Net profit margin %14.79.3 158.1%  
BALANCE SHEET DATA
Current assets Rs m121,878108,141 112.7%   
Current liabilities Rs m86,80638,322 226.5%   
Net working cap to sales %21.345.9 46.4%  
Current ratio x1.42.8 49.8%  
Inventory Days Days13097 133.9%  
Debtors Days Days6874 91.9%  
Net fixed assets Rs m81,037109,411 74.1%   
Share capital Rs m5861,610 36.4%   
"Free" reserves Rs m116,218140,682 82.6%   
Net worth Rs m116,804142,292 82.1%   
Long term debt Rs m4,51236,621 12.3%   
Total assets Rs m211,052228,606 92.3%  
Interest coverage x42.716.3 261.8%   
Debt to equity ratio x00.3 15.0%  
Sales to assets ratio x0.80.7 117.2%   
Return on assets %11.86.7 176.9%  
Return on equity %20.710.0 208.4%  
Return on capital %27.410.0 274.8%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72751,691 156.2%   
Fx outflow Rs m34,70021,033 165.0%   
Net fx Rs m46,02730,658 150.1%   
CASH FLOW
From Operations Rs m19,54814,628 133.6%  
From Investments Rs m-19,570-8,540 229.1%  
From Financial Activity Rs m8,642-3,855 -224.2%  
Net Cashflow Rs m8,9222,431 367.0%  

Share Holding

Indian Promoters % 54.1 16.0 338.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 8.0 12.2 65.2%  
FIIs % 27.7 23.7 116.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.2 26.2 38.9%  
Shareholders   69,601 161,166 43.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   UNICHEM LAB  VENUS REMEDIES  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SUN PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Power and Energy Stocks Witness Buying(12:30 pm)

Share markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the power sector.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 25, 2019 03:19 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS